Compare NAN & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAN | MOBI |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.4M | 383.0M |
| IPO Year | 1998 | 2026 |
| Metric | NAN | MOBI |
|---|---|---|
| Price | $9.57 | $8.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.75 |
| AVG Volume (30 Days) | 192.3K | ★ 211.6K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $71.88 |
| Revenue Next Year | N/A | $43.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $8.45 |
| 52 Week High | $11.80 | $15.19 |
| Indicator | NAN | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 37.09 |
| Support Level | N/A | $8.45 |
| Resistance Level | $11.58 | $11.55 |
| Average True Range (ATR) | 0.18 | 0.77 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 19.76 | 7.67 |
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.